DK1124804T3 - Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntase - Google Patents
Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntaseInfo
- Publication number
- DK1124804T3 DK1124804T3 DK99953259T DK99953259T DK1124804T3 DK 1124804 T3 DK1124804 T3 DK 1124804T3 DK 99953259 T DK99953259 T DK 99953259T DK 99953259 T DK99953259 T DK 99953259T DK 1124804 T3 DK1124804 T3 DK 1124804T3
- Authority
- DK
- Denmark
- Prior art keywords
- cox
- inhibitors
- cyclooxygenase
- biosynthesis
- synthase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 150000003180 prostaglandins Chemical class 0.000 title 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 4
- 108010037464 Cyclooxygenase 1 Proteins 0.000 abstract 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 abstract 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 abstract 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 abstract 2
- 102000001708 Protein Isoforms Human genes 0.000 abstract 2
- 108010029485 Protein Isoforms Proteins 0.000 abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17960598A | 1998-10-27 | 1998-10-27 | |
| US26187299A | 1999-03-03 | 1999-03-03 | |
| US29849099A | 1999-04-23 | 1999-04-23 | |
| US09/427,768 US6307047B1 (en) | 1997-08-22 | 1999-10-27 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1124804T3 true DK1124804T3 (da) | 2005-12-12 |
Family
ID=27497355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99953259T DK1124804T3 (da) | 1998-10-27 | 1999-10-27 | Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntase |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1124804B1 (cs) |
| JP (1) | JP2003512292A (cs) |
| KR (1) | KR100666838B1 (cs) |
| CN (1) | CN1279026C (cs) |
| AT (1) | ATE302759T1 (cs) |
| BG (1) | BG65261B1 (cs) |
| BR (1) | BR9914858A (cs) |
| CA (1) | CA2347982A1 (cs) |
| CZ (1) | CZ300570B6 (cs) |
| DE (1) | DE69926903T2 (cs) |
| DK (1) | DK1124804T3 (cs) |
| ES (1) | ES2249919T3 (cs) |
| HK (1) | HK1041876B (cs) |
| HU (1) | HUP0105248A3 (cs) |
| NO (1) | NO318623B1 (cs) |
| PL (1) | PL198503B1 (cs) |
| SK (1) | SK286806B6 (cs) |
| TR (1) | TR200101765T2 (cs) |
| WO (1) | WO2000024719A1 (cs) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9813998A (pt) | 1997-11-19 | 2000-09-26 | Kowa Co | Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos |
| TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
| JP2000247959A (ja) | 1999-02-26 | 2000-09-12 | Kowa Co | ピリダジン−３−オン誘導体及びこれを含有する医薬 |
| CO5261556A1 (es) | 1999-12-08 | 2003-03-31 | Pharmacia Corp | Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico |
| US6664256B1 (en) | 2000-07-10 | 2003-12-16 | Kowa Co., Ltd. | Phenylpyridazine compounds and medicines containing the same |
| US6716829B2 (en) | 2000-07-27 | 2004-04-06 | Pharmacia Corporation | Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders |
| AR031129A1 (es) | 2000-09-15 | 2003-09-10 | Pharmacia Corp | Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa |
| MY131964A (en) | 2000-09-15 | 2007-09-28 | Pharmacia Corp | 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| US7012098B2 (en) | 2001-03-23 | 2006-03-14 | Pharmacia Corporation | Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers |
| DE10129320A1 (de) | 2001-06-19 | 2003-04-10 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
| AP1822A (en) | 2002-02-14 | 2008-01-30 | Pharmacia Corp | Substituted pyridinones as modulators of P38 MAP kinase. |
| PT1572173E (pt) | 2002-12-13 | 2010-05-10 | Warner Lambert Co | Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior |
| US20040204411A1 (en) * | 2002-12-17 | 2004-10-14 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| ES2211344B1 (es) * | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| BRPI0408359A (pt) | 2003-03-18 | 2006-03-21 | Kowa Co | derivados de fenilpiridazina solúveis em água e medicamentos contendo os mesmos |
| PT1534305E (pt) | 2003-05-07 | 2007-02-28 | Osteologix As | Tratamento de afecções cartilagineas / osseas com sais de estroncio hidrosoluveis |
| ES2251866B1 (es) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| US7728031B2 (en) | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
| EP1916240A1 (en) * | 2006-10-25 | 2008-04-30 | Syngeta Participations AG | Pyridazine derivatives |
| CN102058885B (zh) | 2006-12-22 | 2013-04-10 | 瑞蔻达蒂爱尔兰有限公司 | 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗 |
| DE102007008839A1 (de) | 2007-02-23 | 2008-08-28 | Bayer Healthcare Ag | Verfahren zur Herstellung von 4-(3-Hydroxy-3-methyl-butoxy)-5-[4-(methylsulfonyl)phenyl]-2-arylpyridazin-3(2H)-onen |
| DE102007008843A1 (de) | 2007-02-23 | 2008-08-28 | Bayer Healthcare Ag | Verfahren zur Herstellung von 4,5-Dihalogen-2-aryl-2H-pyridazin-3-onen |
| DE102007008840A1 (de) | 2007-02-23 | 2008-08-28 | Bayer Healthcare Ag | Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy)-5-[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP) |
| DE102007020689A1 (de) * | 2007-05-03 | 2008-11-06 | Bayer Healthcare Ag | Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy-5-[4-methylsulfonyl)phenyl]3/2H)-pyridazinon (FHMP) |
| DE102007020690A1 (de) * | 2007-05-03 | 2008-11-06 | Bayer Healthcare Ag | Neue amorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-mehtyl-1-butoxy)-6[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP) |
| DE102007025717A1 (de) * | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Arylether-pyridazinonderivate |
| GB0716414D0 (en) * | 2007-08-22 | 2007-10-03 | Syngenta Participations Ag | Novel insecticides |
| CN101809021B (zh) | 2007-09-11 | 2013-04-24 | 雅培制药有限公司 | 八氢-吡咯并[3,4-b]吡咯n-氧化物 |
| GB0903493D0 (en) | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
| JP2012131708A (ja) * | 2009-04-28 | 2012-07-12 | Nissan Chem Ind Ltd | ４位置換ピリダジノン化合物及びｐ２ｘ７受容体阻害剤 |
| FR2969606B1 (fr) * | 2010-12-22 | 2013-01-11 | Pf Medicament | Derives de diarylpyridazinones, leur preparation et leur application en therapeutique humaine |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| WO2018049027A1 (en) | 2016-09-07 | 2018-03-15 | Trustees Of Tufts College | Combination therapies using immuno-dash inhibitors and pge2 antagonists |
| CN107334767B (zh) * | 2017-06-08 | 2019-03-05 | 中国医学科学院医药生物技术研究所 | 一种哒嗪酮类化合物在肿瘤治疗中的应用 |
| WO2021124344A1 (en) * | 2019-12-18 | 2021-06-24 | Abida | Pyridazine derivatives and their use as cyclooxygenase-2 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4238490A (en) * | 1979-02-12 | 1980-12-09 | Diamond Shamrock Corporation | Antihypertensive pyridazin(2H)-3-ones |
| BR8108745A (pt) * | 1980-08-07 | 1982-07-06 | Diamond Shamrock Corp | Difenilpiridazinonas herbicidas e reguladores do crescimento da planta |
| US5622948A (en) * | 1994-12-01 | 1997-04-22 | Syntex (U.S.A.) Inc. | Pyrrole pyridazine and pyridazinone anti-inflammatory agents |
| US6342510B1 (en) * | 1995-06-12 | 2002-01-29 | G. D. Searle & Co. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist |
| EP0975604B1 (en) * | 1997-03-14 | 2004-07-21 | Merck Frosst Canada & Co. | Pyridazinones as inhibitors of cyclooxygenase-2 |
| JP2002511887A (ja) * | 1997-08-22 | 2002-04-16 | アボツト・ラボラトリーズ | プロスタグランジンエンドペルオキシドｈシンターゼ生合成阻害薬 |
| JP2003516925A (ja) * | 1997-08-22 | 2003-05-20 | アボット・ラボラトリーズ | プロスタグランジンエンドペルオキシドｈシンターゼ生合成阻害剤としてのアリールピリダジノン |
| EP1007515A1 (en) * | 1997-08-22 | 2000-06-14 | Abbott Laboratories | Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors |
-
1999
- 1999-10-27 PL PL349256A patent/PL198503B1/pl not_active IP Right Cessation
- 1999-10-27 EP EP99953259A patent/EP1124804B1/en not_active Expired - Lifetime
- 1999-10-27 HK HK02101207.5A patent/HK1041876B/en not_active IP Right Cessation
- 1999-10-27 CA CA002347982A patent/CA2347982A1/en not_active Abandoned
- 1999-10-27 ES ES99953259T patent/ES2249919T3/es not_active Expired - Lifetime
- 1999-10-27 KR KR1020017005342A patent/KR100666838B1/ko not_active Expired - Fee Related
- 1999-10-27 BR BR9914858-7A patent/BR9914858A/pt not_active IP Right Cessation
- 1999-10-27 CN CNB998147265A patent/CN1279026C/zh not_active Expired - Fee Related
- 1999-10-27 TR TR2001/01765T patent/TR200101765T2/xx unknown
- 1999-10-27 WO PCT/US1999/025234 patent/WO2000024719A1/en not_active Ceased
- 1999-10-27 DE DE69926903T patent/DE69926903T2/de not_active Expired - Lifetime
- 1999-10-27 CZ CZ20011481A patent/CZ300570B6/cs not_active IP Right Cessation
- 1999-10-27 DK DK99953259T patent/DK1124804T3/da active
- 1999-10-27 SK SK554-2001A patent/SK286806B6/sk not_active IP Right Cessation
- 1999-10-27 JP JP2000578289A patent/JP2003512292A/ja not_active Ceased
- 1999-10-27 HU HU0105248A patent/HUP0105248A3/hu unknown
- 1999-10-27 AT AT99953259T patent/ATE302759T1/de not_active IP Right Cessation
-
2001
- 2001-04-26 NO NO20012061A patent/NO318623B1/no not_active IP Right Cessation
- 2001-05-19 BG BG105523A patent/BG65261B1/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2347982A1 (en) | 2000-05-04 |
| HK1041876A1 (en) | 2002-07-26 |
| ATE302759T1 (de) | 2005-09-15 |
| NO20012061L (no) | 2001-06-27 |
| TR200101765T2 (tr) | 2002-02-21 |
| HK1041876B (en) | 2006-06-23 |
| CN1342149A (zh) | 2002-03-27 |
| PL349256A1 (en) | 2002-07-01 |
| NO318623B1 (no) | 2005-04-18 |
| CZ300570B6 (cs) | 2009-06-17 |
| BR9914858A (pt) | 2002-02-05 |
| CN1279026C (zh) | 2006-10-11 |
| KR100666838B1 (ko) | 2007-01-11 |
| EP1124804B1 (en) | 2005-08-24 |
| SK286806B6 (sk) | 2009-05-07 |
| KR20010081101A (ko) | 2001-08-27 |
| JP2003512292A (ja) | 2003-04-02 |
| HUP0105248A2 (hu) | 2002-07-29 |
| EP1124804A1 (en) | 2001-08-22 |
| HUP0105248A3 (en) | 2002-09-30 |
| BG105523A (en) | 2001-12-29 |
| PL198503B1 (pl) | 2008-06-30 |
| WO2000024719A1 (en) | 2000-05-04 |
| NO20012061D0 (no) | 2001-04-26 |
| CZ20011481A3 (cs) | 2001-09-12 |
| BG65261B1 (bg) | 2007-10-31 |
| ES2249919T3 (es) | 2006-04-01 |
| DE69926903D1 (en) | 2005-09-29 |
| SK5542001A3 (en) | 2001-12-03 |
| DE69926903T2 (de) | 2006-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE302759T1 (de) | Prostaglandin endoperoxyde h synthase biosynthese inhibitoren | |
| DK1005460T3 (da) | Inhibitorer af biosyntesen af prostaglandin-endoperoxid H-synthase | |
| CA2299300A1 (en) | Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors | |
| Reddy et al. | C-Phycocyanin, a selective cyclooxygenase-2 inhibitor, induces apoptosis in lipopolysaccharide-stimulated RAW 264.7 macrophages | |
| Arora et al. | Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: A review | |
| Gedawy et al. | Design, synthesis and biological evaluation of novel pyrazole sulfonamide derivatives as dual COX-2/5-LOX inhibitors | |
| Esser et al. | Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2 | |
| Carabaza et al. | Stereoselective inhibition of inducible cyclooxygenase by chiral nonsteroidal antiinflammatory drugs | |
| Chan et al. | Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles | |
| Pairet et al. | Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs | |
| Feldman et al. | Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? | |
| Chen et al. | Syntheses and biological activities of sulfoximine-based acyclic triaryl olefins | |
| BRPI0011172B8 (pt) | derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2 | |
| Lolli et al. | A new class of ibuprofen derivatives with reduced gastrotoxicity | |
| EP1391201A4 (en) | MEDICAL COMPOSITIONS | |
| Ramalho et al. | The search for new COX-2 inhibitors: a review of 2002–2008 patents | |
| Moneer et al. | Synthesis of novel substituted thiourea and benzimidazole derivatives containing a pyrazolone ring as anti‐inflammatory agents | |
| Singh Bahia et al. | Inhibitors of microsomal prostaglandin E2 synthase‐1 enzyme as emerging anti‐inflammatory candidates | |
| Rasooli et al. | Synergistic effects of deuterium depleted water and Mentha longifolia L. essential oils on sepsis-induced liver injuries through regulation of cyclooxygenase-2 | |
| Naureen et al. | Discovery of indole-based tetraarylimidazoles as potent inhibitors of urease with low antilipoxygenase activity | |
| Aprioku et al. | Renal effects of non-steroidal anti inflammatory drugs in albino rats | |
| Varandas et al. | Design, synthesis and pharmacological evaluation of new nonsteroidal antiinflammatory 1, 3, 4-thiadiazole derivatives | |
| Zhu et al. | Cardioprotective effects of nitroparacetamol and paracetamol in acute phase of myocardial infarction in experimental rats | |
| TR200000478T2 (tr) | Prostaglandin endoperoksit H sentaz biyosentezi inhibitörleri olarak arilpiridazinonlar. | |
| Tavares | The effects of meloxicam, indomethacin or NS‐398 on eicosanoid synthesis by fresh human gastric mucosa |